High-dose intravenous azathioprine pulse treatment in refractory Wegener's granulomatosis

P. M. Aries, B. Hellmich, E. Reinhold-Keller and W. L. Gross

Poliklinik für Rheumatologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck and Rheumaklinik Bad Bramstedt, Germany

Correspondence to: P. Aries, Rheumaklinik Bad Bramstedt, Oskar-Alexander Strasse 26, 24576 Bad Bramstedt, Germany. E-mail: aries{at}rheuma-zentrum.de

SIR, in Wegener's granulomatosis (WG) standard therapy with cyclophosphamide (CYC) is limited by treatment-associated short- and long-term morbidity and mortality as well as insufficient response in about 10% of all cases [1]. Several therapeutic regimes have been used for refractory disease with varied results, including monoclonal antibodies to TNF-{alpha} [2] and different surface markers of T-cells (CD4, CD 52) [3] and B-cells (CD20) [4]. We report two patients with WG responding insufficiently to standard therapy, TNF blockade and rituximab in succession, but treated successfully with intravenous (i.v.) azathioprine (AZA). Both participants who were treated gave their informed consent. They fulfilled the Chapel Hill Consensus Conference definition [5] and the ACR criteria [6] for WG. Diagnosis was based on a typical clinical presentation and biopsy findings, supported by the presence of cANCA/PR3-ANCA. Sufficient activity of thiopurine methyltransferase (TPMT), an inactivating enzyme in the metabolism of AZA, was determined before treatment. AZA (1200 mg in 1000 ml NaCl 0.9% i.v., corresponding to 17 mg/kg body weight) was given over a 24-h period (50 ml/h) once monthly with antiemetic prophylaxis (ondansetron). Additive AZA was given orally (100 mg per day) in weeks 2 and 3 between each pulse, with regular monitoring of the white blood cell count. After completing six pulses, therapy was continued with daily AZA (100–150 mg/day) orally.

Patient 1, a 33-yr-old female with WG and predominantly ENT involvement, was started on CYC (1300 mg every 6 weeks i.v.) and prednisolone (PRD). Because of the development of an increasing retro-orbital mass after 9 months of CYC, therapy was intensified by adding infliximab (5 mg/kg body weight every 6 weeks). Continuing and wearing right-sided supraorbital pain with an increasing demand for PRD (60 mg/day) was attributed to massive progress of the retrobulbar granuloma. Thus, CYC and infliximab were stopped after 28 weeks of combined treatment and rituximab (375 mg/m2) was started in combination with MTX (20 mg/week i.v.) instead. In addition to further progress of the retro-orbital mass, a necrotizing and destructive inflammation of the right-sided lower eyelid soon appeared (Fig. 1). The decision was made to change treatment to i.v. azathioprine pulse therapy (1.2 g). After the first two i.v. applications, less pain and better vision were reported by the patient. Strong improvement continued up to the sixth AZA pulse, and regression of endonasal and orbital disease activity and a better motility of the right eye were documented during the next 12 months (Birmingham Vasculitis Activity Score (BVAS) 1:0, BVAS 2:3).



View larger version (114K):
[in this window]
[in a new window]
 
FIG. 1. Patient with WG and progressive retro-orbital mass and a necrotizing inflammation of the lower eyelid. Patient consent has been obtained for the publication of this photograph.

 
The second patient, a 43-yr-old male, was diagnosed as having WG presenting with remitting scleritis, subglottic stenosis, sensory neuropathy and a retro-orbital granuloma of the right eye with incipient visual loss. Therapy with CYC (150 mg/day orally) and PRD was initiated. After continuous treatment for 6 months the progressive retrobulbar granulomatous lesion continued to threaten his vision. Standard therapy was intensified by adding infliximab (5 mg/kg every 6 weeks). After 12 months of combined therapy, lesions of the right eye had led to a wearing orbital pain and almost extinct visual capacity. In addition, a smaller granuloma of the left eye developed under intensified treatment. Treatment was stopped and local corticosteroid retrobulbar injections were given in the right eye. Rituximab infusions (375 mg/m2) were started at monthly intervals; CYC was continued and PRD doses remained high (25 mg/day). The inflammatory process and the orbital granulomas remained unchanged after four consecutive rituximab applications. Facing progressive visual loss even of the left eye, therapy was switched to i.v. AZA pulse therapy. Changes were noted after two infusions, and during further treatment the retrobulbar pain disappeared totally, progression of the orbital masses stopped and repeated MRIs showed regression and scarring of the granulomas (BVAS 1:0, BVAS 2:0).

We report the successful induction of remission by i.v. AZA pulse therapy in two patients with refractory WG during standard treatment. Intravenous AZA was used initially in inflammatory bowel disease as a loading dose to decrease the time to response and was later proved to be safe and of clinical benefit in a pilot study in patients with ulcerative colitis [7, 8]. AZA is a purine analogue and its postulated mechanism of action is apparently at the level of DNA [9]. As demonstrated recently, AZA and its metabolites play a unique role in the control of T-cell apoptosis by the modulation of Rac1 activation upon CD28 costimulation [10]. Binding of AZA metabolites to the small GTP-binding Rac1 leads to decreased activation of Rac1 target genes, such as NF-{kappa}B and bcl-XL, leading to a mitochondrial pathway of apoptosis.

The authors have declared no conflicts of interest.

References

  1. Savage COS, Harper L, Adu D. Primary systemic vasculitis. Lancet 1997;349:553–7.[CrossRef][ISI][Medline]
  2. Stone JH, Uhloenfelder M, Hellmann D, Crooks S, Bedocs NM, Hoffmann GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open label trial to evaluate safety. Arthritis Rheum 2001;44:1149–54.[CrossRef][ISI][Medline]
  3. Lockwood CM, Thiru S, Lomas D et al. Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune disease. J R Coll Phys 1998;32:473–8.[ISI]
  4. Specks U, Fervenza FC, McDonald J, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836–40.[CrossRef][ISI][Medline]
  5. Jenette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187–92.[ISI][Medline]
  6. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101–7.[ISI][Medline]
  7. Sandborn WJ, Van O EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995;109:1808–17.[ISI][Medline]
  8. Mahadevan U, Tremaine WJ, Johnson T et al. Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J. Gastroenterology 2000;95:3463–8.[ISI][Medline]
  9. Elion GB. The George Hitching and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann N Y Acad Sci 1993;685:400–7.[Medline]
  10. Tiede I, Fritz G, Strand S et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133–45.[Abstract/Free Full Text]
Accepted 8 June 2004





This Article
Full Text (PDF)
Alert me when this article is cited
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Search for citing articles in:
ISI Web of Science (4)
Disclaimer
Request Permissions
Google Scholar
Articles by Aries, P. M.
Articles by Gross, W. L.
PubMed
PubMed Citation
Articles by Aries, P. M.
Articles by Gross, W. L.
Related Collections
Vasculitis